Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Placebo-Controlled, Crossover Study to Examine the Safety and Activity of SXC-2023 to Improve Behavioral Dynamics in Non-Treatment Seeking Adults Undergoing Acute Nicotine Withdrawal

NCT03887429 is registered in ClinicalTrials.gov with Promentis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03887429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03887429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Placebo-Controlled, Crossover Study to Examine the Safety and Activity of SXC-2023 to Improve Behavioral Dynamics in Non-Treatment Seeking Adults Undergoing Acute Nicotine Withdrawal
Lead sponsor
Promentis Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 4, 2019
Completion date
July 9, 2019
Enrollment
34 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

impulse control disorders